期刊文献+

8例郎格汉斯细胞组织细胞增生症患儿Birbeck颗粒的超微结构观察 被引量:1

Ultrastructural features of Birbeck granules in 8 cases with Langerhans cell histiocytosis
下载PDF
导出
摘要 目的探讨郎格汉斯细胞组织细胞增生症(LCH)病损区郎格汉斯细胞(LC)及其中Birbeck颗粒的超微结构,为研究Birbeck颗粒的来源、形态、空间结构提供依据。方法透射电镜观察8例儿童LCH患者病变区LC及Birbeck颗粒的超微结构。结果 8例LCH患儿病损区均可见典型LC,其中6例LC中可见Birbeck颗粒,大部分位于胞浆中,部分位于细胞膜内侧,与细胞膜相连续,细胞膜外也可见Birbeck颗粒样结构存在;典型Birbeck颗粒呈棒状、网球拍样,也可呈不规则形,周围常伴有圆形空泡样结构。结论 Birbeck颗粒可能起源于细胞膜,空间结构可能为不规则形,其形态具有多样性,不规则性,非典型Birbeck颗粒也具有诊断意义。 Objective To observe the ultrastructural features of Langerhans cells (LCs), especially Birbeck granules in Langerhans cell histiocytosis (LCH) and provide the evidence to clarify its origin, function and stereoscopic structure of Birbeck granules. Methods Transmission electron microscope (TEM) was used to detect the ultrastructure of Birbeck granules in 8 patients with LCH. Results All 8 cases showed typical LCs, among which, 6 revealed typical rod- or tennis-racquet-like Birbeck granules. Some Birbeck granules were presented as irregular shapes accompanied with vacuole-like structure. Most Birbeck granules were located in cytoplasma, and some of them were close and merged to the cell membrane. Birbeck granule-like structure could also be observed outside of the cell membrane in one case with muhisystem LCH. Conclusions The ultrastructure of Birbeck granules was presented as diverse and irregular. Those atypical granules were useful for the diagnosis of LCH. Birbeck granules may arise from the cell membrane, and form irregular stereoscopic structure.
出处 《中国小儿血液与肿瘤杂志》 CAS 2013年第3期112-115,共4页 Journal of China Pediatric Blood and Cancer
关键词 郎格汉斯细胞组织细胞增生症 Birbeck颗粒 超微结构 电镜 Langerhans cell histiocytosis Birbeck granules Ultrastructure Electron microscope
  • 相关文献

参考文献13

  • 1Dziegiel P, DoliMska-Krajewska B, DumaAska M, et al. CoexpressionCDla, langerin and Biibeck's granules in Langerhans cell histicx^toses(LCH) in children: ultrastructural and immunocytochemical studies.Folia Histochem Cytobiol, 2007 , 45:21-25.
  • 2吴升华.郎格罕细胞组织细胞增生症评估与治疗指南介绍[J].中华儿科杂志,2012,50(2):155-158. 被引量:67
  • 3Histiocyte Society. Langerhans cell histiocytosis evaluation and treatmentguideline. April, 2009. Availabele from : http : //www. Heama-tologie-amc. nl/odijk. bijlagen.
  • 4Swerdlow SH, Campo E, Harris NL, et al. World Health Organizationclassificati?i oi tumours. WHO classificaticMi ol tumours c haematcoieticand lymphoid tissues. Lyon: IARC Press, 2008 ; 358-360.
  • 5Pavelka M,Roth J. Langerhans cell and Birbeck granules: antigenpresenting dendritic cells of the epidermis. Functional Ultrastructure,2010, part 1, part 4,100-101.
  • 6Valladeau J, Ravel 0, Dezutter-Dambuyant C, et al. Langerin, anovel C-type lectin specific to Langeriians cells, is an endocyticreceptor that induces the formation of Birbeck granules. Immunity,2000, 12 : 71-81.
  • 7Valladeau J,Dezutter-Dambuyant C, Saeland S. Langerin/CD207sheds light on formation of Birbeck granules and their possible ftinctionin Langerhans cells. Immunol Res, 2003,28: 93-107.
  • 8Me Dermott R, Ziylan U, Spehner D, et al. Biifceck granules aresubdomains of endosomal recycling compartment in human epidermalLangerhans cells which form where langerin accumulates. Mol BiolCell, 2002, 13: 317-335.
  • 9Thepaut M,Valladeau J, Nurisso A, et al. Structural studies oflangerin and Birbeck granule : a macromolecular oi^anization model.Biochemistry, 2009, 48: 2684-2698.
  • 10郑晓刚,陈旭东,姜少军,陆珍凤,周晓军.郎格罕氏组织细胞增生症的电镜研究[J].电子显微学报,2006,25(3):250-253. 被引量:4

二级参考文献21

  • 1王宏胜,李军,马伴吟,高怡瑾,陆凤娟,钱晓文.改良DAL-HX83/90方案治疗儿童郎格罕细胞组织细胞增生症24例疗效观察[J].中国小儿血液与肿瘤杂志,2007,12(2):60-63. 被引量:12
  • 2Histiocyte Society. Langerhans cell histiocytosis evaluation and treatment guideline. April,2009. Availabele from : http ://www. heamatologie-amc, nl/odijk/bijlagen.
  • 3Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs, 2011,13 : 75 -86.
  • 4Gadner I-I, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histioeytosis. J Pediatr, 2001, 138:728-734.
  • 5treatment ot multisystem Langerhans cell histiocytosis : important prognostic indicator. Med Pediatr Oncol, 2002,39:581- 585.
  • 6Bernard F, Thomas C, Bertrand Y,et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside corobined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer, 2005,41:2682-2689.
  • 7Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced- intensity conditioning. Bone Marrow Transplant, 2005,36: 215- 225.
  • 8Egeler RM, de Kraker J, Vo6te PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol, 1993,21: 265-270.
  • 9Stine KC, Saylors RL, Williams LL, et al. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol, 1997,29: 288-292.
  • 10Stine KC, Saylors RL, Saccente S, et al. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer, 2004,43:81-84.

共引文献73

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部